Aberdeen, United Kingdom
GLYKOGEN LIMITED is a biopharma startup founded in 2016 with a focus on developing a pipeline of anti-glycan antibodies to target specific, currently ‘hard to treat’ cancers, including pancreatic cancer. The company utilizes an innovative and patentable process to deliver more effective, less-invasive therapies for cancer by targeting cancer cells through their surface glycans, which play a crucial role in almost every biological process and disease. GlykoGen's vision is to address the difficulties in producing antibodies to glycans, thereby exploring their role in cancer.
The unique approach of GlykoGen in targeting cancer cells through glycans makes it an attractive investment opportunity for biotechnology and pharmaceutical investors. As of now, there is no publicly available information on the company's headquarter location, last investment date, or the investors involved in the last funding round.
```
